Kamada

Company Overview

Snapshot

Founded in December 1990 by David Tsur, Kamada operates with 201–500 employees. The company has raised a total of $150 million across 7 funding rounds from 2 investors.

Business overview

Kamada is a plasma-derived protein therapeutics company specializing in the extraction and purification of proteins from human plasma using its proprietary platform technology. The company develops and commercializes a portfolio of FDA-approved products, including GLASSIA for Alpha-1 Antitrypsin (AAT) deficiency and KEDRAB for rabies immune globulin. Kamada serves the health tech and life sciences sectors, with products in late-stage clinical development for conditions such as type 1 diabetes, GvHD, and lung transplant rejection.

Strategic signal

In September 2023, Kamada announced the expansion of its plasma collection operations in Texas with a new site in Houston. This strategic move signals the company's commitment to strengthening its supply chain and increasing its capacity for plasma-derived therapeutics, which is crucial for its product development and commercialization efforts in the biopharmaceutical market.

Company Intelligence Q&A

What was a significant corporate development for Kamada in late 2023?

In October 2023, Kamada announced achievements with CYTOGAM®, including the availability of the product manufactured by the company for U.S. commercial sale and the presentation of new clinical data. This indicates progress in product commercialization and clinical validation.

What was a key strategic acquisition by Kamada?

In February 2021, Kamada acquired an FDA-licensed plasma collection center from Blood and Plasma Research, Inc. in Texas, USA. This acquisition aimed to enhance the company's plasma supply capabilities.

What was a notable supply agreement update for Kamada?

In October 2022, Kamada was awarded a $22 million extension of its Canadian supply tender, reinforcing its market presence and revenue streams in the region.

When did Kamada become publicly traded?

Kamada became public on the TASE in September 2005 and on NASDAQ in June 2008.